US-based StellaPharma has announced that it will acquire G2B Pharma (G2B) and its dry powder nasal formulation of epinephrine for the treatment of anaphylaxis. According to a 2014 press release, G2B had licensed SNBL’s nasal delivery technology and was co-developing G2B011 epinephrine nasal spray with SNBL. Neither StellaPharma nor G2B appears to have a website currently.
G2B Pharma Founder and CEO Nigel Fleming said, “We are excited to see this important product move forward with the StellaPharma team and are eager to contribute to its development and commercial success.”
StellaPharma CEO Steve Stefano said, “A more patient-friendly route for epinephrine delivery is badly needed. A dry-powder nasal spray product holds out the prospect for improving compliance as an alternative to auto-injectors.”
Insys got Fast Track designation for its intranasal epinephrine for the treatment of anaphylaxis in 2018 and recently announced results from a dose finding study. In December 2018, ARS Pharmaceuticals announced that it had raised $20 million for development of an epinephrine nasal spray for the treatment of anaphylaxis.
Read the StellaPharma press release.
